 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- Venclexta (venetoclax) / Roche, AbbVie, TGN-1062 / TGen
TGN-1062, a dual CDK7 and FLT3 Inhibitor, shows potent anti-AML activity and synergizes with Venetoclax (Section 18) - Mar 5, 2024 - Abstract #AACR2024AACR_8363;
Since its approval venetoclax, a BCL2 inhibitor, has been the standard treatment for older patients in combination with a hypomethylating agent (HMA), such as azacitidine or decitabine, with a 76% complete response (CR). Targeting CDK7 with TGN-1062 in combination with venetoclax or an HMA is a promising therapeutic approach for treatment of AML and needs further investigation.
- TGN-1062 / TGen
Inhibition of CDK7 using small molecule inhibitor, TGN-1062, augments the effect of cisplatin treatment in head and neck PDX models (Section 14; Poster Board #24) - Mar 14, 2023 - Abstract #AACR2023AACR_4910;
Targeting CDK7 with TGN-1062 in combination with SOC therapy is a promising approach for treatment of HNSCC. TGN-1062 is a potent CDK7 inhibitor with potential for clinical development.
- TGN-1062 / TGen, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
TGN-1062 inhibits CDK7 and augments the effects of gemcitabine and nab-paclitaxel in pancreatic cancer models (Section 22) - Mar 9, 2022 - Abstract #AACR2022AACR_6020;
Our potent and selective small molecule inhibitor of CDK7, TGN-1062, shows promise in pancreatic cancer models as a single or in combination with SOC . Preliminary data suggests that TGN-1062 can be developed further in multiple cancer indications.
- TGN-1062 / TGen
[VIRTUAL] Preclinical studies with TGN-1062, a selective and reversible small molecule inhibitor of CDK7 () - Mar 11, 2021 - Abstract #AACR2021AACR_459;
TGN-1062 is a novel, selective, and reversible inhibitor of CDK7 and has significant antitumor activity in vivo. TGN-1062 is a potent CDK7 inhibitor with potential for clinical development.